Results 191 to 200 of about 106,568 (297)

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer

Taiwanese Journal of Obstetrics & Gynecology, 2017
Chia-Hao Liu, Yi Chang
doaj   +1 more source

Poly (ADP-Ribose) Polymerase 1 and 2 in B-Cell Lymphoma: Pathogenic Roles and Therapeutic Implications. [PDF]

Am J Pathol
Molina-Alvarez A, Sanchez-Gonzalez B, Colomo L, Yélamos J.   +3 more
europepmc   +1 more source

Poly [ADP-Ribose] Polymerase 3 [PDF]

, 2020
openaire   +1 more source

Homoisoflavonoids—From Natural Specificity and Biosynthesis to Precision Health‐Promoting Mechanisms

Food Frontiers, Volume 7, Issue 3, May 2026.
Homoisoflavonoids are rare flavonoids with a unique bi‐aromatic oxygen‐heterocyclic structure. This review synthesizes their structure–activity relationships in anti‐inflammatory, hypoglycemic, and anticancer contexts. By highlighting their specific natural distribution and outlining biosynthetic pathways, it provides a conceptual framework and ...
Jing Zhang, Han Chen, Jinping Si, Zhigang Han, Xinfeng Zhang   +4 more
wiley   +1 more source

Poly(ADP-ribose)polymerase 2 is zinc-dependent enzyme and nucleosome reorganizer. [PDF]

Cell Mol Life Sci
Maluchenko N, Saulina A, Geraskina O, Kotova E, Korovina A, Armeev G, Kirpichnikov M, Feofanov A, Studitsky V.   +8 more
europepmc   +1 more source

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang, Charvi Nanavati, Derek Z. Yang, Liza DeAnnuntis, Mohamed Elmeliegy   +4 more
wiley   +1 more source

R2eGIN: Residual Reconstruction Enhanced Graph Isomorphism Network for Accurate Prediction of Poly (ADP-Ribose) Polymerase Inhibitors. [PDF]

Bioinform Biol Insights
Zonyfar C, Njimbouom SN, Mosalla S, Kim JD.   +3 more
europepmc   +1 more source

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Niraparib is a poly(ADP‐ribose) polymerase inhibitor approved for maintenance treatment of advanced ovarian cancer. Using data from a previous niraparib population pharmacokinetic (PK) model with data from four studies, this model added phase 1 pharmacokinetic data from two studies.
Anna Gaffney, Yoko Franchetti, Mathieu Desrosiers, Mirjam N. Trame, Roxanne C. Jewell   +4 more
wiley   +1 more source

DNA Copy Number Profiling in Extracellular Vesicles as Clinical Biomarkers of High‐Grade Serous Ovarian Carcinoma

Journal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.
ABSTRACT Extracellular vesicles (EVs), including exosomes, circulate in body fluids and carry pathological genomic information. High‐grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, characterized predominantly by copy number variations (CNVs).
Ryosuke Uekusa, Akira Yokoi, Mayu Ukai, Kosuke Yoshida, Kunanon Chattrairat, Takao Yasui, Yasuhide Inokuma, Masami Kitagawa, Eri Asano‐Inami, Masato Yoshihara, Satoshi Tamauchi, Nobuhisa Yoshikawa, Kaoru Niimi, Juntaro Matsuzaki, Takahiro Ochiya, Anil K. Sood, Yusuke Yamamoto, Hiroaki Kajiyama   +17 more
wiley   +1 more source

Poly (ADP-Ribose) Polymerase Inhibition Attenuates Atherosclerotic Plaque Development in ApoE-/- Mice with Hyperhomocysteinemia. [PDF]

J Atheroscler Thromb
Xie JJ, Yu X, Liao YH, Chen J, Yao R, Chen Y, Liao MY, Ding YJ, Tang TT, Cheng X.   +9 more
europepmc   +1 more source